•  
  •  
 

Peer Reviewed

1

DOI

10.17077/2154-4751.1226

Abstract

A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.

Keywords

Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor

Total Pages

2 pages

Rights

Copyright © Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robet S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle, 2013.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Share

COinS